Potent vs moderate‐potency topical corticosteroid
- Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 99 participantsVery low
It is very uncertain whether weekend therapy changes systemic adverse events: abnormal cortisol; end of treatment (16… compared with no topical corticosteroid (very low certainty).
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes adverse effects Mild abdominal pain and nausea Adverse effects Mild… compared with placebo (very low certainty).
Potent/very potent topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).
Topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).
Mild/moderate topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).